Q2 Report 2022 – invitation to conference call and audiocast

Stockholm, July 15, 2022 – On Friday, July 22, at 09.00 CET, IRRAS will host a conference call and an online presentation of its Q2 2022 interim report (which will have been published earlier on July 22 at 08.00 CET). The presentation will be held in English.

The dial-in numbers for the conference call are:

Sweden: +46 8 50 51 63 86
UK: +44 203 198 4884
US: +1 412 317 6300
Pin code: 8395073#

The presentation will be webcast and can be accessed from the following web address:


Speakers: President and CEO Will Martin, Interim CFO Griffen Stapp, and Head of Investor Relations Sten Gustafsson


IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

Sten Gustafsson
Director, Investor Relations
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on July 15, 2022 at 8:30 (CET).

Irras Radio Irras Academy

At IRRAS, your privacy and the protection of your personal data are important to us. To ensure GDPR compliance, this website does not store or track any personal information, including Google Analytics or form submission data.
By using the website, you acknowledge and accept our policy.